Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO Private Facebook Group
to join : go to
or contact
Ubiome Gut EXPLORER : 10% OFF
Join/Watch the weekly
TMAU UP Podcasts

Videos : TMAU stories

Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect

£ 943.03/GBP
$ 568.00/USD

TOTAL at today's ROE
£0.80/GBP = $1.00/USD

£1,398.07 = $1,745.14



Your currency will be automatically converted to USD or GBP by PayPal.

Option: pay with your credit card instead of PayPal account by clicking on either Donate button above.

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

Thursday, January 8, 2009

The phase 1/phase 2 biotransformation enzymes

body odor
Note: This is the author's interpretation of the article referenced below, and therefore, may not be wholly accurate

In our quest to understand bloodborne odor problems as best we can, this is another post about the xenobiotic metabolizing enzymes, also known as the drug metabolizing enzymes or biotransformation enzymes. This is the group of enzymes largely responsible for dealing with external foreign compounds, and altering them into something the body knows what to do with - in the case of toxins, turning them into water soluble non-toxic compounds. These enzymes also catalyze metabolic processes with internal compounds. They deal with compounds of similar structures.

At the moment, these seem like a natural parameter for looking for a 'metabolic' culprit(s) in fecal body odor and other 'non-specific' metabolic body odors. Other enzymes seem to be quite specific for certain substrates, and perhaps a sufferer will have a certain smell only, such as 'sweaty feet syndrome' with isovaleric acidemia. But at the moment this is speculation. We don't want to rule anything out, but this group of cell enzymes seem the first point of enquiry.

Xenobiotic enzymes are mostly situated in the liver cells, but are also present in cells anywhere the body, as the evolutionary process over the generations has deemed sensible. (e.g. the small intestine. Grapefruit juice can greatly inhibit CYP3A4 activity in the small intestine, but seemingly not the CYP3A4 in the liver). Phase1 seems to be enzymes that catelyses oxidation, reduction or hydrolyze reactions. Phase2 enzymes are known as 'conjugating enzymes'; they add a molecule to a compound to make it neutral and water soluble. For instance, in sulfation, a sulfur molecule is added.

The phase1/phase2 approach may not be commonly used, yet possibly still taught to medical students. Currently FMO3 is likely not given as much importance compared to CYP450 as is noted in the article, Flavin mono-oxygenase (FMO)--the 'other' oxidase, by an FMO3 expert (Mitchell SC in London). Some may see their point, since most with TMAU seem to be 'fine' apart from the smell. But other health problems may turn out to be associated. Such as chronic fatigue, or aggravation to other medical conditions such as neurological conditions (learning disabilities, anxiety, epilepsy, fibromyalgia, auto-immune diseases, etc.) . Only time will tell.

Medical students are likely taught that any 'deficiency' in a xenobiotic metabolizing enzyme is likely to do with a phase 1 enzyme, and that phase 2 are rarely deficient, but 5% (or more) of the population are estimated to have a weak 'glucuronidation' enzyme. This is regarded as usually 'benign' but testimonies on the problem seem to indicate differently. Often the sufferer will easily develop jaundiced, since this enzyme is greatly responsible for detoxing bilirubin. It's known as Gilberts Syndrome.

Hopefully the CYP450 article below will add to understanding these enzymes.


Post a Comment